Concepedia

Lisa Rossius

LR

3

Publications

2.2K

Citations

3

H-Index

2014

Active since

Affiliations

Bayreuth Medical Center(Current)

Ludwig-Maximilians-Universität München

Lukaskrankenhaus

Krankenhaus Nordwest

Klinikum St. Marien Amberg

Lisa Rossius is an author at Bayreuth Medical Center specializing in colorectal cancer, cancer therapeutics, and radiation oncology.

Top concepts

MedicineOncologyPathologyCancer TherapyColorectal CancerRadiation OncologyCancer ResearchMolecular OncologyHealthCancer Genetics

Publications per year

2014–2016

3

Publications

3

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Cetuximab Versus Folfiri, Oncology, Clinical Trials +9

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 410 citations

Cetuximab Versus Folfiri, Gastrointestinal Oncology, Tumour Dynamics +10

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

Sebastian Stintzing, Andreas Jung, Lisa Rossius et al. · Journal of Clinical Oncology · 2014 · 97 citations

Fire-3 Study, Medicine, Plus Folfiri +13

Rows per page

1–3 of 3